Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04173065 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH
A Phase 2 study, sponsored by Viking Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 248
- Enrollment target
NCT04173065 is a Phase 2 study that has completed, run by Viking Therapeutics. The registered enrollment target is 248 participants.
The verdict
NCT04173065, a Phase 2 study, has completed, sponsored by Viking Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 248 participants
- Enrollment target
Study Summary
The study includes 52 weeks, double-blind treatment period. Clinic visits will occur at Randomization and every four weeks from Week 4 through Week 52 and through End of Study period. The study includes a post-dosing study visit that will occur 4 weeks after the last dose of study drug. This visit represents the End-of-Study Visit (Week 56 Visit). Three hundred thirty-seven subjects will be enrolled into five treatment arms and there will be an equal distribution of males and females in each treatment arm. Subjects will be stratified by gender, fibrosis stage, and diabetes status.
Interventions
- DRUG Placebos
- DRUG VK2809
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2024-01-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04173065
The ClinicalTrials.gov registry entry for NCT04173065 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viking Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT04173065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04173065 about?
NCT04173065 is a clinical study titled "A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH". The study includes 52 weeks, double-blind treatment period. Clinic visits will occur at Randomization and every four weeks from Week 4 through Week 52 and through End of Study period. The study includes a post-dosing study visit that will occur 4 weeks after the last dose of study drug. This visit r...
What is the current status of trial NCT04173065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 248 participants. The study started on 2019-11-15. Estimated completion is 2024-01-26.
What interventions are being tested in trial NCT04173065?
The interventions under investigation include: Placebos (DRUG), VK2809 (DRUG).
Who is sponsoring clinical trial NCT04173065?
This trial is sponsored by Viking Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.